These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22623208)

  • 41. Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis.
    van der Galiën R; Boveneind-Vrubleuskaya NV; Peloquin C; Skrahina A; Touw DJ; Alffenaar JC
    Clin Pharmacokinet; 2020 Jul; 59(7):899-910. PubMed ID: 31981103
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.
    Xiang H; Liu L; Gao Y; Ahene A; Collins H
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):899-910. PubMed ID: 34383128
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.
    Li H; Han TH; Hunder NN; Jang G; Zhao B
    J Clin Pharmacol; 2017 Sep; 57(9):1148-1158. PubMed ID: 28513851
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.
    Kuester K; Kovar A; Lüpfert C; Brockhaus B; Kloft C
    Clin Pharmacokinet; 2009; 48(7):477-87. PubMed ID: 19691369
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Permanent central venous catheter in pediatric oncology].
    Nielsen PA; Jøhncke H; Due E
    Ugeskr Laeger; 1989 Jun; 151(23):1470-2. PubMed ID: 2734952
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A population pharmacokinetic meta-analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects.
    Edwards AY; Elgart A; Farrell C; Barnett-Griness O; Rabinovich-Guilatt L; Spiegelstein O
    Br J Clin Pharmacol; 2017 Sep; 83(9):1932-1943. PubMed ID: 28294391
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dexmedetomidine Pharmacology in Neonates and Infants After Open Heart Surgery.
    Su F; Gastonguay MR; Nicolson SC; DiLiberto M; Ocampo-Pelland A; Zuppa AF
    Anesth Analg; 2016 May; 122(5):1556-66. PubMed ID: 26218862
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal Clearance.
    Béranger A; Benaboud S; Urien S; Moulin F; Bille E; Lesage F; Zheng Y; Genuini M; Gana I; Renolleau S; Hirt D; Tréluyer JM; Oualha M
    Clin Pharmacokinet; 2019 Feb; 58(2):223-233. PubMed ID: 29862466
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds.
    Yun YE; Edginton AN
    J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients.
    Chelle P; Yeung CHT; Bonanad S; Morales Muñoz JC; Ozelo MC; Megías Vericat JE; Iorio A; Spears J; Mir R; Edginton A
    J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):427-438. PubMed ID: 31115857
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reasons for participation in optional pharmacokinetic studies in children with cancer: a Children's Oncology Group phase 1 consortium study.
    Berg SL; Winick N; Ingle AM; Adamson PC; Blaney SM
    Pediatr Blood Cancer; 2010 Jul; 55(1):119-22. PubMed ID: 20486176
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population Pharmacokinetic Model of Dexmedetomidine in a Heterogeneous Group of Patients.
    Ber J; Wiczling P; Hołysz M; Klupczyńska A; Bartkowska-Śniatkowska A; Bieda K; Smuszkiewicz P; Nowicka M; Żurański Ł; Sobczyński P; Matysiak J; Grześkowiak E; Bienert A
    J Clin Pharmacol; 2020 Nov; 60(11):1461-1473. PubMed ID: 32500578
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain.
    Xu XS; Smit JW; Lin R; Stuyckens K; Terlinden R; Nandy P
    Clin Pharmacokinet; 2010 Oct; 49(10):671-82. PubMed ID: 20818833
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetic analysis of AR-67, a lactone stable camptothecin analogue, in cancer patients with solid tumors.
    Tang F; Tsakalozou E; Arnold SM; Ng CM; Leggas M
    Invest New Drugs; 2019 Dec; 37(6):1218-1230. PubMed ID: 30820810
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.
    Hennig S; Norris R; Kirkpatrick CM
    Br J Clin Pharmacol; 2008 Apr; 65(4):502-10. PubMed ID: 17995972
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies.
    Dosne AG; Valade E; Stuyckens K; Li LY; Ouellet D; Perez-Ruixo JJ
    J Clin Pharmacol; 2020 Apr; 60(4):515-527. PubMed ID: 31742712
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment.
    Peigné S; Fouliard S; Decourcelle S; Chenel M
    J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):29-43. PubMed ID: 26578442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Peripherally inserted central catheters in the treatment of children with cancer: Results of a multicenter study.
    Rykov MY; Zaborovskij SV; Shvecov AN; Shukin VV
    J Vasc Access; 2018 Jul; 19(4):378-381. PubMed ID: 29546772
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Model-Aided Adults-to-Children Pharmacokinetic Extrapolation and Empirical Body Size-Based Dosing Exploration for Therapeutic Monoclonal Antibodies-Is Allometry a Reasonable Choice?
    Xu Y; Langevin BA; Zhou H; Xu Z
    J Clin Pharmacol; 2020 Dec; 60(12):1573-1584. PubMed ID: 32578225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.